Articles on MHC & TCR

The interaction between MHC molecules and T-cell receptors (TCRs) is central to immune system function and therapeutic design. This category highlights key developments in MHC/TCR research, immunotherapy strategies, and biotech-driven solutions.

Featured Article

TCR Therapy Targeting MAGE-A4

Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its T cell receptor-engineered T cell (TCR-T) therapy, Afamitresgene autoleucel (afami-cel), for synovial sarcoma. The results showed that the overall response rate of afami-cel was 39% and the median duration of response was 50 weeks [1].